Temozolomide exposure and delivery barriers in glioma: cross-compartment pharmacokinetics and implications for resistance

Temozolomide (TMZ) remains central to glioblastoma therapy, yet treatment failure reflects both pharmacodynamic resistance and incomplete exposure across relevant intracranial compartments. In this evidence-audited narrative review, we trace TMZ from the systemic circulation across the blood–brain and blood–brain tumor barriers to regional distribution, cellular uptake or export, intracellular retention, chemical activation, and DNA damage. Combined adenosine triphosphate (ATP)-binding cassette subfamily B member 1 (ABCB1)/ATP-binding cassette subfamily G member 2 (ABCG2) deficiency increases brain penetration in mice without changing systemic exposure, supporting a contribution from endothelial transport; however, evidence that individual tumor-cell transporters directly export TMZ is heterogeneous and includes negative findings. Transporter-mediated influx and vesicular partitioning further indicate that inadequate uptake or intracellular removal can be mistaken for classical efflux. Human cerebrospinal fluid and brain-interstitial studies demonstrate partial, compartment-dependent penetration, whereas focused-ultrasound studies support the feasibility of barrier opening. Survival outcomes from single-arm studies cannot be attributed to ultrasound without a randomized comparison. A focused full-text audit of 15 TMZ-containing delivery-platform studies identified extensive formulation and efficacy reporting but only three studies with direct analyte-specific measurements targeting parent TMZ in biological samples. These measurements were limited to plasma or whole blood and single-time-point total-tissue extracts of whole brain or brain tumor; none established regional unbound parent-TMZ pharmacokinetics. We propose a claim–evidence framework that separates direct transport and pharmacokinetic evidence from functional sensitization, association, delivery-concept, and negative evidence. Linking parent-drug exposure, regional distribution, pharmacodynamic competence, safety, and clinical feasibility can help determine when inadequate exposure is a modifiable component of glioma resistance.

Authors

Institutions

Publication Details

Journal
Cancer Drug Resistance
Published
2026-11-18
DOI
https://doi.org/10.20517/cdr.2026.129
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Temozolomide exposure and delivery barriers in glioma: cross-compartment pharmacokinetics and implications for resistance

Congcong Ma, Zhaoxing Jia, Yuhui Zhao, Tianxiang Jiang et al.
Cancer Drug Resistance
Glioma Diagnosis and Treatment
article

Temozolomide exposure and delivery barriers in glioma: cross-compartment pharmacokinetics and implications for resistance

Congcong Ma, Zhaoxing Jia, Yuhui Zhao, Tianxiang Jiang, Xiaokai Cen, Weiping Zhang, Xianming Lin, Wen Chen, Kecheng Qian, Tao Li, Lin Gan
article en

Abstract

Temozolomide (TMZ) remains central to glioblastoma therapy, yet treatment failure reflects both pharmacodynamic resistance and incomplete exposure across relevant intracranial compartments. In this evidence-audited narrative review, we trace TMZ from the systemic circulation across the blood–brain and blood–brain tumor barriers to regional distribution, cellular uptake or export, intracellular retention, chemical activation, and DNA damage. Combined adenosine triphosphate (ATP)-binding cassette subfamily B member 1 (ABCB1)/ATP-binding cassette subfamily G member 2 (ABCG2) deficiency increases brain penetration in mice without changing systemic exposure, supporting a contribution from endothelial transport; however, evidence that individual tumor-cell transporters directly export TMZ is heterogeneous and includes negative findings. Transporter-mediated influx and vesicular partitioning further indicate that inadequate uptake or intracellular removal can be mistaken for classical efflux. Human cerebrospinal fluid and brain-interstitial studies demonstrate partial, compartment-dependent penetration, whereas focused-ultrasound studies support the feasibility of barrier opening. Survival outcomes from single-arm studies cannot be attributed to ultrasound without a randomized comparison. A focused full-text audit of 15 TMZ-containing delivery-platform studies identified extensive formulation and efficacy reporting but only three studies with direct analyte-specific measurements targeting parent TMZ in biological samples. These measurements were limited to plasma or whole blood and single-time-point total-tissue extracts of whole brain or brain tumor; none established regional unbound parent-TMZ pharmacokinetics. We propose a claim–evidence framework that separates direct transport and pharmacokinetic evidence from functional sensitization, association, delivery-concept, and negative evidence. Linking parent-drug exposure, regional distribution, pharmacodynamic competence, safety, and clinical feasibility can help determine when inadequate exposure is a modifiable component of glioma resistance.

Cancer Drug Resistance
Zhejiang Chinese Medical University (CN), The Third Affiliated Hospital of Zhejiang Chinese Medical University (CN)
Zhejiang Chinese Medical University
Good health and well-being
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon